Custom cancer vaccine shows promise in early pancreatic cancer trial
NCT ID NCT05111353
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 35 times
Summary
This early-phase trial tested personalized neoantigen vaccines in 33 pancreatic cancer patients who had already received chemotherapy. The vaccines were designed to target unique mutations in each person's tumor and were given with an immune booster called poly-ICLC. Some patients received the vaccine before surgery, others after. The main goal was to check safety and see if the vaccine could activate the immune system against the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized neoantigen synthetic long peptide vaccine with poly-ICLC (Hiltonol)
What this could lead to
If successful, this could point toward a new way to train the immune system to fight pancreatic cancer, potentially improving outcomes after standard treatment.
What could go wrong
This is a very early (Phase 1) and small trial (33 people) focused on safety, not effectiveness. The vaccine is custom-made for each patient, which is complex and may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.